Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting β2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy ...

Mylan N.V. has announced that it has launched the first bioequivalent alternative to GlaxoSmithKline's Seretide® Evohaler® (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla™ ...

The uniformity of delivered dose, or dose content uniformity, was assessed to understand the performance of the Sirdupla generic product versus the Seretide Evohaler innovator product. Analytical ...

Brokerage Bank of America Merrill Lynch (BoAML) feels the launch of asthma drug by Mylan in the UK is negative for Cipla because earlier the drug maker was expected to be the first company to launch ...

CANONSBURG (Alliance News) - Mylan NV Monday said that it has launched what it claims is the first bioequivalent alternative to GlaxoSmithKline's Seretide Evohaler under the brand name Sirdupla in the ...

Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting beta2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy[1],[2] ...